Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 6Carcinoid Tumor 5Acromegaly 5Pituitary Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Liver Neoplasms 2Growth Disorders 2Gigantism 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Thyroid Neoplasms 1Serotonin Syndrome 1Prolactinoma 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary ACTH Hypersecretion 1Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Dumping Syndrome 1Carcinoma, Neuroendocrine 1Carcinoma, Medullary 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma 1

Interventions

Mifepristone 3Corlux 3relacorilant 2Cabergoline 2pasireotide 1corticorelin ovine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pituitary ACTH Hypersecretion × pasireotide × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡